Literature DB >> 15605661

Impaired brachial endothelial function in patients with primary anti-phospholipid syndrome.

F Mercanoglu1, D Erdogan, H Oflaz, R Kücükkaya, F Selcukbiricik, A Gül, M Inanc.   

Abstract

Although the precise pathophysiology of thrombosis is unknown in primary anti-phospholipid syndrome (PAPS), it is assumed that autoantibodies developed against endothelial cells and platelets might be one of the primary mechanisms. However, whether interaction between autoantibodies and endothelium leads to an impaired vasodilator response has not been investigated yet. In this study, we aimed to investigate the endothelial functions in patients with PAPS. Thirty-one patients with PAPS (22 female, nine male, mean age: 34.6+/-8.9 years) and 27 age- and sex-matched, healthy controls were included in the study. Brachial artery responses to reactive hyperaemia (endothelium-dependent dilatation) [EDD] and sublingual nitroglycerine (endothelium-independent dilatation) [EID] were measured by using high-resolution vascular ultrasound both in patients with PAPS and in the controls. The results were expressed as percentage of change in baseline values. Regarding cardiovascular risk factors, there was no significant difference between the two groups. EDD in patients with PAPS was significantly lower than those of controls (6.9+/-4.9 vs. 14.8+/-4.1%; p<0.0001). EID measurements were not significantly different between the groups. In the PAPS group, EDD in patients with arterial involvement (17 patients) was significantly lower than those of patients with venous involvement (12 patients) (4.6+/-3.9 vs. 7.4+/-4.1%; p = 0.02). This study showed that endothelial functions determined by using brachial artery ultrasound were impaired in patients with PAPS, and this was more prominent in the subgroup of patients with arterial involvement compared to patients with venous involvement.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15605661     DOI: 10.1111/j.1742-1241.2004.00162.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  7 in total

1.  Endothelial dysfunction in patients with antiphospholipid syndrome assessed with positron emission tomography.

Authors:  Erick Alexanderson; Patricio Cruz; Angélica Vargas; Aloha Meave; Alejandro Ricalde; Jose A Talayero; José Luis Romero-Ibarra; Tovë M Goldson; Olga L Vera-Lastra; Gabriela Medina; Luis Jara; Mary-Carmen Amigo
Journal:  J Nucl Cardiol       Date:  2007-07-02       Impact factor: 5.952

2.  Decreased flow-mediated dilatation with increased arterial stiffness and thickness as early signs of atherosclerosis in polymyositis and dermatomyositis patients.

Authors:  Melinda Vincze; H Dér; Gy Kerekes; P Szodoray; M Zeher; K Dankó; P Soltész
Journal:  Clin Rheumatol       Date:  2014-03-12       Impact factor: 2.980

3.  Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2.

Authors:  Sangeetha Ramesh; Craig N Morrell; Cristina Tarango; Gail D Thomas; Ivan S Yuhanna; Guillermina Girardi; Joachim Herz; Rolf T Urbanus; Philip G de Groot; Philip E Thorpe; Jane E Salmon; Philip W Shaul; Chieko Mineo
Journal:  J Clin Invest       Date:  2010-12-01       Impact factor: 14.808

Review 4.  Vascular Manifestations in Antiphospholipid Syndrome (APS): Is APS a Thrombophilia or a Vasculopathy?

Authors:  Salma Siddique; Jessie Risse; Guillaume Canaud; Stéphane Zuily
Journal:  Curr Rheumatol Rep       Date:  2017-09-04       Impact factor: 4.592

5.  Lipid peroxidation as risk factor for endothelial dysfunction in antiphospholipid syndrome patients.

Authors:  Natasa Stanisavljevic; L Stojanovich; D Marisavljevic; A Djokovic; V Dopsaj; J Kotur-Stevuljevic; J Martinovic; L Memon; S Radovanovic; B Todic; D Lisulov
Journal:  Clin Rheumatol       Date:  2016-08-25       Impact factor: 2.980

6.  Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: Role of reduced inflammation and endothelial dysfunction.

Authors:  Sébastien Miranda; Paul Billoir; Louise Damian; Pierre Alain Thiebaut; Damien Schapman; Maelle Le Besnerais; Fabienne Jouen; Ludovic Galas; Hervé Levesque; Véronique Le Cam-Duchez; Robinson Joannides; Vincent Richard; Ygal Benhamou
Journal:  PLoS One       Date:  2019-03-14       Impact factor: 3.240

Review 7.  Role of anti-beta2 glycoprotein I antibodies in antiphospholipid syndrome: in vitro and in vivo studies.

Authors:  Pier Luigi Meroni; Nicoletta Ronda; Valentina De Angelis; Claudia Grossi; Elena Raschi; Maria Orietta Borghi
Journal:  Clin Rev Allergy Immunol       Date:  2007-02       Impact factor: 10.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.